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BACKGROUND: Immune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse events (irAE). We sought to
determine if CTCAE classification, IBD biomarkers/endoscopic/histological scores correlate with irAE colitis outcomes.
METHODS: A dual-centre retrospective study was performed on patients receiving ICI for melanoma, NSCLC or urothelial cancer
from 2012 to 2018. Demographics, clinical data, endoscopies (reanalysed using Mayo/Ulcerative Colitis Endoscopic Index of Severity
(UCEIS) scores), histology (scored with Nancy Index) and treatment outcomes were analysed.
RESULTS: In all, 1074 patients were analysed. Twelve percent (134) developed irAE colitis. Median patient age was 66, 59% were
male. CTCAE diarrhoea grade does not correlate with steroid/ infliximab use. G3/4 colitis patients are more likely to need infliximab
(p < 0.0001) but colitis grade does not correlate with steroid duration. CRP, albumin and haemoglobin do not correlate with severity.
The UCEIS (p= 0.008) and Mayo (p= 0.016) scores correlate with severity/infliximab requirement. Patients with higher Nancy
indices (3/4) are more likely to require infliximab (p= 0.03).
CONCLUSIONS: CTCAE assessment does not accurately reflect colitis severity and our data do not support its use in isolation, as
this may negatively impact timely management. Our data support utilising endoscopic scoring for patients with >grade 1 CTCAE
disease, and demonstrate the potential prognostic utility of objective histologic scoring.
British Journal of Cancer https://doi.org/10.1038/s41416-020-0882-y
BACKGROUND
Immune checkpoint inhibitors (ICIs) have become standard-of-
care treatment for melanoma,1,2 and more recently for non-small-
cell lung cancer (NSCLC)3 and renal cancer.4 In metastatic
melanoma they have revolutionised care, raising the median
life-expectancy from months to years, and leading to long-term
remission in a growing proportion of cases.1
Immune checkpoint proteins regulate immune activation to limit
inflammatory responses. In the presence of persistent antigen, these
evolutionarily conserved pathways mediate immune response
‘exhaustion’, reducing the inflammatory stress inflicted on the
organism. Checkpoint proteins are expressed on various immune
cell subsets, including (but not restricted to) T cells, B cells, and
dendritic cells.
Licensed ICIs fall into several categories: anti-cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) (ipilimumab, tremeli-
mumab), anti-programmed cell death protein-1 (PD-1) (nivolu-
mab, pembrolizumab, cemiplimab) and anti-programmed death
ligand-1 (PD-L1) (avelumab, atezolizumab, and durvalumab). PD-1
inhibition can be used as monotherapy, in combination with
chemotherapy for NSCLC, or in combination with CTLA-4
inhibitors in metastatic melanoma and renal cell carcinoma. Use
of ICIs is predicted to increase substantially in the coming years for
an expanding range of cancers both as single agents and in
combination regimens.5–7
As their mode of action is to aid T-cell activation, it is
unsurprising that ICIs also have an immune-mediated side-effect
profile. These immune-related adverse events (irAEs) most
commonly affect epithelia (e.g. skin and gastrointestinal (GI)
tract), but also solid organs (resulting in hepatitis,8 pancreatitis,
and thyroiditis9). Inflammation of the GI tract (enterocolitis) is the
most frequent cause of significant morbidity and cessation of ICI. It
may rarely lead to life-threatening complications such as colonic
perforation. Combination therapy with CTLA-4 and PD-1 inhibitors
is associated with a significantly higher incidence and severity of
irAEs (including colitis) than single-agent PD-1 inhibition.10
Oncological guidelines developed from clinical trials’ data
recommend using the National Cancer Institute’s Common
www.nature.com/bjc
Received: 19 December 2019 Revised: 6 April 2020 Accepted: 24 April 2020
1Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK; 2NIHR Oxford Biomedical Research Centre, Oxford University Hospitals
NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, UK; 3The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Birkenhead, Wirral CH63 4JY,
UK; 4Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool L69 3BX, UK; 5Department of Gastroenterology, Royal Liverpool University Hospital, Royal
Liverpool and Broadgreen University Hospitals NHS Trust, Prescot Street, Liverpool L7 8XP, UK; 6Department of Cellular Pathology, John Radcliffe Hospital, University of Oxford,
Oxford OX3 9DU, UK and 7Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford OX3 7LE, UK
Correspondence: Vincent Ting Fung Cheung (vincent.cheung@doctors.org.uk)
These authors contributed equally: Vincent Ting Fung Cheung, Tarun Gupta, Anna Olsson-Brown
© The Author(s) 2020 Published by Springer Nature on behalf of Cancer Research UK
Terminology Criteria for Adverse Events (CTCAE),11 to diagnose
and assess severity of diarrhoea and colitis.12–14 The GI CTCAE is
based predominantly on clinical symptoms (i.e. stool frequency
over baseline for assessing diarrhoea; and abdominal pain, blood
in stools, peritoneal signs, and life-threatening consequences for
assessing colitis). It is unclear whether CTCAE grading correlates
with subsequent outcomes and guidance of management
decisions. If we can identify patients who are likely to have
protracted course at outset, we could then introduce additional
immunosuppression earlier in the disease course. The utility of
CTCAE has not been tested in terms of its effectiveness in
diagnostics and prognostication of immunotherapy-related colitis
(irAE colitis).
In idiopathic inflammatory bowel disease (IBD), it has been
increasingly recognised that objective markers are required to
accurately assess disease severity and aid clinical decision-making.
Examples include combined clinical and biochemical scores like
Truelove and Witts criteria15 for acute severe ulcerative colitis (UC),
which correlates with requirement for rescue therapy or
colectomy,16 and validated endoscopic scoring like the Ulcerative
Colitis Endoscopic Index of Severity (UCEIS),17 which correlates
with UC outcomes.18 More recent data in IBD suggest that using
histological scores in UC, such as the Nancy index,19 can most
accurately predict clinical outcomes.20 Recent reports suggest
endoscopic and histological assessment of irAE colitis may also
correlate with disease outcomes.21,22
Guidelines advise using corticosteroids as first-line treatment for
irAE colitis with anti-TNFα therapy (infliximab) second line.12–14 In
practice, there is considerable variation in the initiation, dose
number and frequency of infliximab administration. For irAE colitis
patients with not only steroid-responsive but also steroid-
dependent disease, there is no consensus on when or how to
escalate therapy.
We have analysed a large cohort of ICI-treated patients to
describe the real-world incidence, assessment, and management
of irAE colitis in two tertiary referral centres. With regards to irAE
colitis, we sought to:
1. describe real-world practice of its management;
2. determine the utility of the CTCAE classification of diarrhoea
and of colitis grade as a tool for its assessment and
prognosis;
3. determine whether established IBD biochemical markers (C-
reactive protein (CRP), haemoglobin or albumin) correlate
with disease outcome;
4. determine whether IBD endoscopic scores or histological
scores correlate with clinical outcome;
5. describe the treatment outcomes when current guidelines
are followed.
METHODS
An observational retrospective cohort study was performed
from January 2012 to October 2018 at the Clatterbridge Cancer
Centre NHS Foundation Trust (linked with Royal Liverpool
University Hospitals NHS Trust) and Oxford University Hospitals
NHS Foundation Trust.
Patient selection
All adult patients who received ICI (ipilimumab, nivolumab,
pembrolizumab, ipilimumab+ nivolumab (combination)) for
metastatic melanoma, NSCLC or renal/urothelial cancer as
standard-of-care were included. Using the electronic patient
record (EPR) and oncology prescribing database (at Oxford, EPR
is Cerner Millennium® and oncology prescriptions are made
using Aria®; at Liverpool, Meditech is used for both systems),
patient demographics, clinical data, endoscopic and histopatho-
logical reports, and treatment outcomes were recorded. All irAE
enterocolitis patients had GI symptoms presenting after ICI
administration. Patients where an alternative diagnosis was
made, e.g. infection or use of non-steroidal anti-inflammatory
drugs, were excluded. Monitoring for ICI response was generally
performed every 3 months.
Definition of diarrhoea and irAE colitis
We conducted a comprehensive review of the EPR and oncology
prescribing databases to confirm the diagnosis of ICI-related
diarrhoea or colitis based on the decision of the treating
oncologist or gastroenterologist. Diarrhoea was defined on CTCAE
version 5.0 11 on review during data collection using the primary
data. irAE colitis was defined as diarrhoea requiring steroid/
infliximab therapy for resolution and/or with endoscopic/histolo-
gical confirmation. Oncology guidelines on managing ICI-related
colitis do not currently mandate endoscopic assessment, and
therefore patients are mostly initiated on steroid treatment prior
to endoscopy.12–14 Onset of colitis was defined from start of ICI to
date of diarrhoea.
Severity of colitis
There is no standard way of assessing severity apart from CTCAE,
which as a predominantly subjective clinical score is of uncertain
value. Patients were, therefore, divided into severity categories
depending on the nature and length of treatment required to
achieve colitis resolution. A standard weaning steroid course for
an IBD flare is 60 days so we used this as one delineator of
outcome and severity. Patients were divided into three categories:
(1) mild-moderate colitis where diarrhoea settled rapidly following
a course of steroids ≤60 days; (2) refractory or moderate-severe
colitis requiring steroids >60 days; and (3) severe colitis requiring
infliximab ‘rescue therapy’.
IBD biomarkers
Markers commonly used in UC to assess severity and prognos-
ticate (CRP and haemoglobin in Truelove & Witts score,15 or
albumin in the Ho index23) were analysed to determine if they
correlated with severity of colitis and treatment outcome.
Endoscopic analysis
We analysed the subset of patients for whom endoscopic data
were available (n= 40, 30%) in a blinded fashion with Joint
Advisory Group on gastrointestinal endoscopy (JAG)-accredited
endoscopists (V.T.F.C. and O.B.) separately scoring the images
taken at endoscopy on UCEIS17,24 and Mayo scores25 (Supple-
mentary Fig. 1a, b). Where there was disagreement, V.T.F.C. and O.
B. assessed the images again and came to a consensus. Both
endoscopists and pathologists were blinded during scoring to
clinical outcome.
Histological analysis
We analysed a subset of patients for whom histological slides were
available (n= 45). Two expert GI pathologists, E.F. and E.C.,
separately scored the slides on the presence (or absence of)
ulceration, acute inflammatory cells infiltrate and chronic inflam-
matory infiltrate then calculated the Nancy index19 (Supplemen-
tary Fig. 1c). The histopathologists then assigned an overall
histological pattern grading to each patient based on one of the
following types:
● focal active colitis—occasional foci of acute inflammation, in
the absence of chronic inflammation or significant crypt injury;
● lymphocytic colitis—increase in intraepithelial and lamina
propria lymphocytes, in the absence of crypt architectural
distortion;
● collagenous colitis—increase in thickness of the subepithelial
collagen plate and increased lamina propria lymphocytes, in
the absence of crypt architectural distortion;
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● IBD-like—active chronic inflammation with goblet cell deple-
tion and crypt architectural distortion;
● Non-steroidal anti-inflammatory drug (NSAID) /infectious-like
—predominantly acute, superficial inflammation with attenua-
tion of crypt and/or surface epithelium.
The histological specimens analysed against treatment
outcome were all acquired at the index scope when diagnosing
irAE colitis, and prior to infliximab use. There was a discrepancy
between the number of endoscopies (n= 40) and histopathol-
ogy scored (n= 45) because only endoscopies with adequate
images were included in the analysis. We also analysed
all available paired data (from both index and follow-up
sigmoidoscopies) to determine whether endoscopic scoring
correlates in general with histological scoring in irAE enteroco-
litis (n= 80).
Statistical analysis
Continuous data are presented with mean (with range) or median
with interquartile range. Non-continuous data are presented as
patient numbers and percentages. Differences between groups
were determined using the unpaired non-parametric Mann
−Whitney, Kruskal−Wallis test or Brown−Forsythe (one-way)
ANOVA. Categorical data were compared by the non-parametric
Fisher’s exact or chi-squared test. To determine if there is a linear
relationship between variables, least squares fit was used. Survival
curves were calculated using the Mantel−Cox method. Statistical
analysis was performed using Graphpad PRISMTM (Ver 8.1) and
IBM SPSSTM (Ver 25) software. A p value < 0.05 was considered
statistically significant, and where multiple comparisons were
performed a Bonferroni correction was made as detailed in
individual table legends.
RESULTS
Presentation and treatment of irAE colitis
A total of 1074 patients were identified across the two centres
(Table 1) with 12% (n= 134) of patients developing colitis with a
median time of onset 60 days (IQR 28−88 days). There was a
predominance of male patients in the cohort (59%), and a median
age of 66 (Supplementary Table 1). Patients who developed G4
diarrhoea did so earlier after ICI induction (median onset 33 days)
than those who developed milder G1/2 diarrhoea (median onset
60 days). Sixty-three percent of patients were admitted, with the
median inpatient stay being 7 days. Time to irAE colitis, hospital
stays related to colitis and treatments used are shown in Table 1.
Patients treated with combination therapy had a significantly
higher risk of developing colitis vs. those treated with monotherapy
(Fig. 1a; 32% vs 9%; p < 0.0001). Treatment with single-agent ICI
resulted in a later onset of colitis compared to those patients given
combination therapy (Fig. 1b). Twenty-two percent of patients
received rescue therapy with infliximab either as single or multiple
doses (Fig. 1c) at a median of 50 days (Fig. 1c inset), with three
undergoing a colectomy (2.3%; two had ipilimumab and one had
combination). Median time to giving infliximab was 13.5 days with
maximum out to 76 days (Supplementary Fig. 2a). Time to giving
infliximab did not correlate with the duration of colitis after receiving
the infliximab (i.e. earlier infliximab does not equal shorter colitis for
our cohort) (Supplementary Fig. 2b). Patients receiving two more
doses of infliximab had no statistically significant difference in
duration of diarrhoea (Supplementary Fig. 2c), although this could
be confounded, and our study is not designed to answer this
specific question. Treatment data were missing for two patients, so
the treatment analysis includes 132 patients.
Figure 1d shows the treatment required for resolution of irAE
colitis by immunotherapy type with combination therapy patients
Table 1. Clinical features and management outcomes of patients with ICI-related colitis. p value in column denotes differences between Group A,
Group B and Group C by Kruskal−Wallis test for continuous data or chi-square test for categorical data.
Group A: Ipilimumab
monotherapy
(n= 189)
Group B: Anti-PD-1
monotherapy
(n= 728)
Group C: Combination
ipilimumab and nivolumab
(n= 157)
p value Total
Patients with colitis (n, %) 42 (22) 41 (6) 51 (32) 2 × 10−23 134 (13)
Onset of colitis since start of treatment (median days,
interquartile range)
64 (35–91) 69 (29–150) 40 (20–65)††, ‡ <0.05 60 (28–88)
Median age of colitis patients (years,
interquartile range)
67 (57–76) 70 (58–76) 63 (56–68) <0.05 66 (57–72)
Male sex in colitis patients (n, %) 28 (67) 23 (56) 30 (59) 0.95 81 (60)
Colitis patients with hospital admission 17 (40) 19 (46) 38 (75) <0.0001 64 (48)
Days to first admission from onset of diarrhoea
(Median, interquartile range)
4 (3–6) 3 (0–5) 5 (3–10)†† <0.05 4 (3–7)
Time from colitis onset to endoscopy (Median,
interquartile range)
12 (4–18)
Length of first hospital stay in days for patients
requiring admission (median, interquartile range)
4 (3–8) 5 (3–8) 6 (3–10) 0.37 5 (3–9)
Treatment
Any steroids (n, %) 38 (90) 29 (71) 50 (98) <0.001 117 (87)
IV steroids (n, %) 12 (29) 14 (34) 38 (75) <0.001 58 (43)
Days of IV steroids in those receiving (median,
interquartile range)
3 (2–4) 5 (3–8) 4 (3–6) 0.16 4 (3–6)
Total days on any steroids (median,
interquartile range)
59 (51–92) 60 (31–102) 66 (49–117) 0.53 62 (47–100)
Infliximab (n, % total) 4 (10) 8 (20) 17 (33) <0.01 29 (22)
Colectomy (n, % total) 2 (5) 0 (0) 1 (2) 0.35 3 (2)
Note patients who had anti-PD-1 therapy then anti-CTLA-4 therapy sequentially (or vice versa) because of progression on first-line treatment were recorded as
monotherapy at the time of colitis.
n/a not applicable.
††p< 0.01 compared with Group B by Mann−Whitney test.
‡p < 0.03 compared with Group A by Mann−Whitney test with Bonferroni correction.
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more likely to require infliximab compared to anti-CTLA-4 or PD-1
monotherapy. For those patients who responded to steroids alone,
the duration of steroids required was shorter in those receiving anti-
PD-1 monotherapy (median 25 days) compared to either anti-CTLA4
monotherapy (56 days) or combination therapy (54 days) (Fig. 1e).
There was no statistical difference in the duration of steroids in
those who received infliximab and steroids, and those treated with
steroid monotherapy for >60 days (median 92 and 94 days; Table 1).
Contrary to a previous report,26 our data did not show that giving
infliximab earlier led to shorter duration of colitis (Supplementary
Fig. 3), although our study was not designed to answer this specific
question. In three patients in our cohort, immunosuppression in
addition to steroids and infliximab was used and improved the
symptoms (vedolizumab in two and mycophenolate mofetil in one;
all were melanoma patients who had combination therapy).
Unlike in idiopathic IBD, there was no clear association
between smoking status and irAE colitis susceptibility in our
cohort (Supplementary Fig. 4). Differences in age and sex were
also not associated with incidence of irAE colitis (Supplementary
Fig. 4). In a sub-group of 456 patients, those patients with prior
IBD (n= 8) and those with other autoimmune diseases (n= 29)
were successfully treated with ICI without flares, and these
patients were not at an increased risk of developing irAE colitis
(Supplementary Fig. 5). All patients continued prior maintenance
IBD therapy throughout the duration of ICI.
A sub-group analysis showed that there was no difference in
overall survival between those that developed irAE colitis and
those that did not, nor in those that had infliximab and those that
did not (Supplementary Fig. 6).
CTCAE as predictor of disease severity and clinical course
CTCAE classification of diarrhoea correlates poorly with duration of
steroids and infliximab requirement, which were used as indirect
markers of irAE colitis severity. In this analysis the CTCAE was only
able to differentiate patients with G1 diarrhoea from the
remainder of patients in terms of duration of steroids (Fig. 2a).
There was no statistical association between CTCAE grade of
diarrhoea and infliximab requirement (Fig. 2b). Seventy percent of
our cohort were recorded as having moderate diarrhoea (G2/3),
which afforded little discriminatory prognostic value (Fig. 2c).
Immunotherapy toxicity guidelines12–14 and local treatment
protocols advise escalation to infliximab for grade 3/4 colitis if
symptoms persist despite corticosteroids beyond 72 h. In line with
expectations, these patients were therefore more likely to be
treated with infliximab (Fig. 2d). However, as with CTCAE grade of
diarrhoea, the CTCAE grade of colitis was unable to prognosticate
between grades 2, 3 and 4 of colitis in terms of duration of
steroids (Fig. 2e). Figure 2f shows the proportion of patients with
each CTCAE grade of colitis and this is similar to the breakdown by
CTCAE grade of diarrhoea.
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Fig. 1 Presentation and treatment of immunotherapy-induced (irAE) colitis in this cohort (n= 1074) of patients. a The incidence of colitis
in single vs. combination immunotherapy (9% vs. 32%; Fisher’s exact test: p < 0.0001). b Onset of colitis after immunotherapy initiation
(median 40 days in combination therapy vs. 68 days in monotherapy; Mann−Whitney test: p= 0.001). c 22% or 29 patients required infliximab
for resolution of their colitis. Median duration of steroids in those who were treated with steroids alone was 50 days. d Number of patients
requiring steroids monotherapy vs. steroids plus infliximab rescue therapy for treatment of their colitis; subdivided by immunotherapy
regimen. Percentages requiring infliximab denoted in figure. Chi-squared test: p= 0.005 for difference between the CTLA4 and the
combination therapy groups. e Mean duration of steroids in patients whose colitis responded to steroid monotherapy alone (patients
requiring infliximab excluded); subdivided by immunotherapy regimen (median 56 days in anti-CTLA-4, 25 days in anti-PD-1, 54 days in
combination; ANOVA: p= 0.04) (N.B. Data unavailable for 50% of patients in the aCTLA4 cohort).
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Blood parameters as predictor of disease severity and clinical
course
CRP, albumin, and haemoglobin do not correlate with severity of
irAE colitis (Fig. 3a−c). There were insufficient measures of faecal
calprotectin in this dataset to be used as part of this analysis.
Endoscopic predictors of disease severity and clinical course
There was moderately good inter-observer correlation for both
UCEIS (kappa= 0.51, SE= 0.09) and Mayo scores (kappa= 0.54,
SE= 0.09) as assessed by Landis and Koch criteria. We found a
reasonable correlation between both UCEIS and Mayo scores and
clinical outcome (Fig. 4a, b), and this includes both steroid
duration and infliximab use. Erosions were most strongly
associated with infliximab requirement (odds ratio 7.0) (Fig. 4c).
The discordance between the CRP and albumin and the UCEIS
score (Fig. 4d, e) within the subset of patients who underwent
sigmoidoscopy further supports the finding that traditional
biochemical markers used in idiopathic IBD are of limited use in
the assessment of irAE colitis. Figure 4f demonstrates some typical
endoscopic findings in irAE colitis.
Histologic predictors of disease severity and clinical course
Figure 5a shows the spectrum of histological subtypes seen in irAE
colitis. None of the irAE colitis patients had prior NSAID use or had
infection, so the NSAID/ infectious-like type histology classification
is for those patients who had histological features consistent
with a NSAID-related colitis or an infectious colitis. Our data
demonstrate a modest correlation between endoscopic severity
(as measured by UCEIS score) and histologic severity (as measured
by Nancy index; Fig. 5b).
Of the microscopic colitis patients, four had collagenous
colitis (one had UCEIS 0, two had UCEIS 1 and one had UCEIS 3)
and nine had lymphocytic colitis (two had UCEIS 0, one had
UCEIS 1, five had UCEIS 2 and one had UCEIS 4). Therefore, only
three patients with microscopic colitis histologic pattern had
completely normal endoscopic appearances. There were a
further eight patients with UCEIS/ Mayo score of 0 who had
mild histological inflammation—two focal active colitis, three
IBD-like and three NSAID/ infectious-like.
There is a trend towards those having IBD-like pattern or NSAID/
infectious-like pattern being more likely to require infliximab
rather than responding to steroids alone (Fig. 5c). None of the
patients in our cohort had granulomas. Those patients with a
higher Nancy index score (3 and 4) were significantly more likely
to require infliximab (Fig. 5d).
DISCUSSION
We present a retrospective review of 1074 patients given ICI over a
7-year period in two large tertiary centres with 12% developing
colitis (consistent with trial data).
Our data suggest that there are no pre-treatment predictive
factors that associate with risk of irAE colitis. We confirm
that combination ICI is associated with a higher incidence of
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Fig. 2 CTCAE as predictor of disease severity and clinical course. a Duration of steroids by CTCAE grade of diarrhoea shows difference
between G1 and higher (G1 median 27 days, G2 64 days, G3 64 days, G4 73 days) (Kruskal−Wallis G1 vs. rest: p= 0.002) but no difference
between other grades (Kruskal−Wallis: p= 0.92) (N.B. Treatment duration data not available for 15% (20) of patients). b Requirement for
infliximab by CTCAE grade of diarrhoea shows no difference (chi-squared test: p= 0.18). c Proportion of patients by CTCAE grade of diarrhoea.
d Requirement for infliximab by CTCAE grade of colitis shows patients with grade 3/4 colitis were more likely to be treated with infliximab
than those with grade 1/2 (Fisher’s exact: p < 0.0001). e Duration of steroids by CTCAE grade of colitis shows difference between G1 and higher
(G1 median 22 days, G2 58 days, G3 85 days, G4 65 days) (Kruskal−Wallis G1 vs. rest: p= 0.002) but no difference between other grades
(Kruskal−Wallis: p= 0.23). f Proportion of patients by CTCAE grade of colitis.
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irAE colitis, earlier presentation and an increased requirement for
intravenous steroids and infliximab. We demonstrate for the first
time that there is no association between colitis development and
smoking status.
The current CTCAE gradings for irAE diarrhoea and colitis, which
are heavily reliant on subjective symptom scores, are not accurate
enough to be relied on alone as tools for diagnosis and treatment
decisions. This has implications for existing clinical guidelines and
trial design. Patients with G1 diarrhoea or colitis are more likely to
require a shorter duration of steroids, but otherwise CTCAE
diarrhoea grades are unable to clearly discriminate steroid respon-
siveness or infliximab use. CTCAE colitis grades 3/4 do associate with
infliximab use, although as current guidelines suggest infliximab
treatment at these grades, interpretation of this as an objective scale
is challenging. There is no association between steroid duration and
CTCAE colitis scores 2, 3 and 4. These data suggest CTCAE will, in a
significant proportion of patients, provide an inaccurate guide to
clinicians regarding the severity of the colitis and the need for
treatment escalation.
Our data suggest that biochemical parameters, conventionally
used for assessing outcomes in ulcerative colitis, are of limited use
for prognostication in irAE colitis. This apparent lack of utility of
well-defined biochemical thresholds may reflect that the ICI
patient population is older and more comorbid than a typical IBD
patient population. CRP is often raised in cancer and haemoglobin
often lowered, further complicating interpretation of these tests.
Further work is needed to determine if monitoring the change in
CRP is useful during treatment of severe irAE colitis.
In our retrospective analysis, endoscopic assessment of irAE
colitis is predictive of treatment outcome. Both UCEIS and Mayo
scores correlate with steroid duration and need for infliximab.
The presence of erosions at endoscopy increases the odds
of requiring infliximab seven-fold, complementing previous
reports.27,28
We have demonstrated for the first time that an objective UC
histological score (Nancy Index) correlates with the clinical course
of irAE colitis. Importantly the histology score is not purely a
surrogate for endoscopic severity, as the correlation between the
two is modest. Moreover, whilst the endoscopic scoring is open to
the criticism of circular reasoning (a more severe macroscopic
appearance may prompt clinicians to use infliximab), the
histologic scoring was performed in blinded fashion after colitis
resolution. The relationship between objective endoscopic and
histologic scores and colitis outcome will need prospective
testing, but our data suggest this will provide additional more
accurate and objective information to clinicians. This is attractive
given the current (and typically sole) use of CTCAE as the
assessment and monitoring tool, as its objective performance is
patchy at best.
The fact that patients treated with infliximab and steroids
have an equally long course of steroids as those treated with
steroid alone suggests that infliximab therapy, when used along
current conventional guidelines, is only modestly effective. This
may partly reflect the inadequacy of basing treatment decisions
on CTCAE grade alone. Although some patients respond rapidly,
there were a substantial number of patients in whom infliximab
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does not appear to provide a steroid-sparing effect. A recent
publication presented data that earlier use of infliximab might
be beneficial for colitis resolution26 and another demonstrated
vedolizumab may be used in steroid-dependent or refractory
cases.29 Whilst we agree this makes intuitive sense, we are
unable to confirm with our data the association between earlier
instigation of infliximab and more rapid colitis resolution
(Supplementary Fig. 2b). This may be owing to the limited
sample size and the fact this is real-world data from two centres
with heterogeneous practice. Only 42% of patients were able to
wean steroids within 60 days without recurrence in the steroid
monotherapy group. The remaining patients required either a
prolonged course of steroids (21%), and/or additional therapy
(infliximab ± vedolizumab ±mycophenolate mofetil) (22%). For
the remainder of patients (15%), the duration of steroid
monotherapy could not be ascertained. A substantial proportion
of patients are, therefore, at risk of steroid side-effects from
prolonged courses. Maximising infliximab efficacy, aiming for
both rapid symptom resolution and reduced steroid use, may be
increased by earlier decision making and administering a full
induction course (three doses). At present there is no clear
consensus on how to enhance care of these patients, but earlier
and more accurate clinical decision-making is likely to be
improved using objective easy-to-use scores like UCEIS and
Nancy Index.
The strengths of our study are the size of the real-world dual-
centre cohort, the fact that it includes data from inpatients and
outpatients, both CTLA-4 and PD-1 inhibitors, and patients with
various cancer types. The data have been collected from high-
volume tertiary oncology and IBD centres that manage referrals
from regional and national levels.
We recognise the limitations of the study, including that this is a
retrospective dataset and that, even between two centres,
considerable heterogeneity will exist in both the clinical assess-
ment and management of this condition. In a retrospective
dataset there is a risk of circular reasoning regarding endoscopic
severity and treatment choice i.e. seeing ulcers may influence
the clinician to assess the disease more severe. However, the
histologic scoring was not determined until after colitis resolution.
Given the indications for ICIs are increasing rapidly, the
incidence of GI irAE will continue to rise. A greater understanding
of baseline risk factors, disease biomarkers and prognostic factors
is much needed.
We demonstrate that the currently recommended CTCAE
grading is inadequate as an assessment tool in terms of
diagnostics and prognostication. Our data suggest that objec-
tive endoscopic and histological scores are the most accurate
methods of ascertaining disease severity and need for rescue
therapy. We would advocate early flexible sigmoidoscopy, using
endoscopic and histological scores, for those with suspected
irAE colitis, particularly for any patient with CTCAE > G1 disease.
Given our data, and previous publications indicating the
relevance of endoscopic assessment, we suggest that clinical
management guidelines are changed to incorporate new
algorithms for the detection, investigation and management
of irAE colitis. Their development and validation will require
larger prospective cohorts.
ACKNOWLEDGEMENTS
We acknowledge Drs. Boddy, Rudra, Harrogate and Liew who helped us to collect
some of the dataset and Dr. Rubeta Matin who provides dermatological
management of patients in the melanoma clinic at Oxford Cancer and Haematology
Centre. We are grateful to the staff of the Day Treatment Units at the Oxford Cancer
and Haematology Centre and Clatterbridge Cancer Centre for their invaluable
assistance. We acknowledge that some of this manuscript has been presented as an
abstract at the 15th Congress of European Crohn’s and Colitis Organisation in
Vienna in February 2020.30
AUTHOR CONTRIBUTIONS
V.T.F.C., T.G. and A.O.-B. contributed equally to the manuscript and should be
considered joint first authors. V.T.F.C. and O.B. devised the article. V.T.F.C., T.G., S.C.S.,
A.O.-B., J.H., S.S., and J.J.S. collected the data. V.T.F.C., T.G., S.C.S. and O.B. analysed the
data and drafted the original article. M.R.M., M.J.P., B.P.F., M.T., A.S.P., M.C., J.J.S., M.P.,
A.O.-B., J.H., O.B. and V.T.F.C. were involved in the clinical management of the
patients. V.T.F.C. and O.B. scored the endoscopies independently. V.T.F.C., T.G., A.O.-B.,
S.S., S.C.S., J.H., E.F., E.C., J.J.S., M.P., A.S., P.K., M.T., A.S.P., M.C., B.P.F., M.J.P., M.R.M. and
O.B. edited and contributed to the intellectual content of this original article and
reviewed the article prior to submission.
ADDITIONAL INFORMATION
Ethics approval and consent to participate This research forms part of the
preliminary work for the ethics-approved PRedicting Immunotherapy Side Effects
(PRISE) Study (London-Surrey Research Ethics Committee: REC18/LO/0412) and the ‘A
Mechanistic Investigation into Drug and Chemical Induced Hypersensitivity Reactions
(HYST)’ study (REC12/NW/0525). The patients who had endoscopy assessment in
Oxford also consented to participation within the ‘Gastrointestinal Illness in Oxford:
prospective cohort for outcomes, treatment, predictors and biobanking’ (16/YH/
0247). Appropriate Caldicott approvals are in place. The study was performed in
accordance with the Declaration of Helsinki.
Consent to publish All patients starting immune checkpoint inhibitors gave written
informed consent for their clinical data to be used for teaching and publications
within the remit of the Oxford University Hospital Trust GI Biobank or the
Clatterbridge Cancer Centre Biobank, which have been approved by institutional
ethics committees.
Data availability The authors confirm that the data supporting the findings of this
study are available within the article and its supplementary materials. Supplementary
information is available at the British Journal of Cancer’s website.
Competing interests V.T.F.C. has received speaker fees from Janssen. A.O.-B. is an
MRC Clinical Training Fellow based at the University of Liverpool supported by the
North West England Medical Research Council Fellowship Scheme in Clinical
Pharmacology and Therapeutics, which is funded by the Medical Research Council,
Roche Pharma, Eli Lilly and Company Limited, UCB Pharma, Novartis, the University of
Liverpool and the University of Manchester. She has received honoraria for speaking
at educational events from Roche Pharma, Bristol-Myers-Squibb (BMS) and MSD. She
has received honoraria for attending BMS advisory boards. J.J.S. has received speaker
fees from BMS and Pierre Fabre; acted as a consultant for BMS, MSD, Amgen, Delcath
and Immunocore; and his institution has received research grants from BMS and AZ.
M.P. is the director of the North West England Medical Research Council Fellowship
Scheme in Clinical Pharmacology and Therapeutics. M.R.M. has acted as a consultant
for Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Immunocore,
Lilly, Merck, Millennium, Novartis, Physiomics, Rigontec, and Roche; his institution has
received research grants from Abbvie, Amgen, AstraZeneca, Bristol-Myers Squibb,
Clovis, Eisai, GlaxoSmithKline, Immunocore, Merck, Millennium, Novartis, Pfizer,
Rigontec, Roche, and Vertex. O.B. has received speaker fees from BMS and has
received a research grant from Celgene. M.T. has performed Advisory/Consultancy
work for Pfizer, Novartis, Lilly, Janssen, Roche, Vaccitech, BMS, and has been a paid
speaker for and received paid speaking engagements and education support from
Novartis, Pfizer, Roche, Janssen, BMS, Genomic Health, Astellas, Esai, Everything
Genetics. A.P. has received honoraria from Ipsen, Roche Bayer, Merck and BMC; and
has received non-financial support from Ipsen and grants from Merck. The other
authors have no conflicts of interest.
Funding information The research was supported by the National Institute for
Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views
expressed are those of the author(s) and not necessarily those of the NHS, the
NIHR or the Department of Health. V.T.F.C. is funded by grants from the Norman
Collisson Foundation and Oxfordshire Health Services Research Committee (OHSRC),
part of Oxford Hospitals Charity. T.G. is supported by a clinical training fellowship
from the Lee Placito Fund. S.C.S. is funded by an Oxford-Celgene Postdoctoral
Fellowship. B.P.F. is supported by a Wellcome Intermediate Clinical Fellowship
(201488/Z/16/Z). A.O.-B. is supported by a Medical Research Council (MRC) Clinical
Research Fellowship (MR/N025989/1). A.S. is supported by a Wellcome Investigator
Award and UK Medical Research Council.
Supplementary information is available for this paper at https://doi.org/10.1038/
s41416-020-0882-y.
Immune checkpoint inhibitor-related colitis assessment and prognosis: can. . .
VTF Cheung et al.
8
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Wolchok, J., Kluger, H., Callahan, M., Postow, M., Rizvi, N., Lesokhin, A. et al.
Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133
(2013).
2. Hodi, F., O’Day, S., McDermott, D., Weber, R., Sosman, J., Haanen, J. et al. Improved
survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.
363, 711–723 (2010).
3. Garon, E., Rizvi, N., Hui, R., Leighl, N., Balmanoukian, A., Eder, J. et al.
Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med.
372, 2018–2028 (2015).
4. Motzer, R., Escudier, B., McDermott, D., George, S., Hammers, H., Srinivas, S. et al.
Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.
373, 1803–1813 (2015).
5. Herbst, R., Soria, J.-C., Kowanetz, M., Fine, G., Hamid, O., Gordon, M. et al.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in
cancer patients. Nature 515, 563–567 (2014).
6. Mariotto, A., Yabroff, K., Shao, Y., Feuer, E. & Brown, M. Projections of the cost of
cancer care in the United States: 2010−2020. J. Natl. Cancer Inst. 103, 117–128
(2011).
7. Webster, R. The immune checkpoint inhibitors: where are we now? Nat. Rev. Drug
Discov. 13, 883–884 (2014).
8. Cheung, V., Gupta, T., Payne, M., Middleton, M., Collier, J., Simmons, A. et al.
Immunotherapy-related hepatitis: real-world experience from a tertiary centre.
Frontline Gastroenterol. 10, 364–371 (2019).
9. Michot, J., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S.
et al. Immune-related adverse events with immune checkpoint blockade: a
comprehensive review. Eur. J. Cancer 54, 139–148 (2016).
10. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Cowey, C., Lao, C. et al. Com-
bined nivolumab and ipilimumab or monotherapy in untreated melanoma. N.
Engl. J. Med. 373, 23–34 (2015).
11. U.S. Department of Health and Human Services. Common terminology
criteria for adverse events (CTCAE). Version 5.0. (2017). https://ctep.cancer.gov/
protocolDevelopment/electronic_applications/docs/
CTCAE_v5_Quick_Reference_8.5x11.pdf.
12. Haanen, J., Carbonnel, F., Robert, C., Kerr, K., Peters, S., Larkin, J. et al. Manage-
ment of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up†. Ann. Oncol. 28(suppl_4), iv119–iv142 (2017).
13. Brahmer, J., Lacchetti, C., Schneider, B., Atkins, M., Brassil, K., Caterino, J. et al.
Management of immune-related adverse events in patients treated with immune
checkpoint inhibitor therapy: American society of clinical oncology clinical
practice guideline. J. Clin. Oncol. 36, 1714–1768 (2018).
14. Puzanov, I., Diab, A., Abdallah, K., Bingham, C., Brogdon, C., Dadu, R. et al.
Managing toxicities associated with immune checkpoint inhibitors: consensus
recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity
Management Working Group. J. Immunother. Cancer 5, 95 (2017).
15. Truelove, S. Cortisone in ulcerative colitis final report on a therapeutic trial.
Br. Med. J. 2, 1041–1048 (1955).
16. Travis, S., Farrant, J., Ricketts, C., Nolan, D., Mortensen, N., Kettlewell, M. et al.
Predicting outcome in severe ulcerative colitis. Gut 38, 905–910 (1996).
17. Travis, S., Schnell, D., Krzeski, P., Abreu, M., Altman, D., Colombel, J. et al. Reliability
and initial validation of the ulcerative colitis endoscopic index of severity.
Gastroenterology 145, 987–995 (2013).
18. Corte, C., Fernandopulle, N., Catuneanu, A., Burger, D., Cesarini, M., White, L. et al.
Association between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
and outcomes in acute severe ulcerative colitis. J. Crohns Colitis 9, 376–381
(2015).
19. Marchal-Bressenot, A., Salleron, J., Boulagnon-Rombi, C., Bastien, C., Cahn, V.,
Cadiot, G. et al. Development and validation of the Nancy histological index for
UC. Gut 66, 43–49 (2017).
20. Ponte, A., Pinho, R., Fernandes, S., Rodrigues, A., Alberto, L., Silva, J. et al. Impact of
histological and endoscopic remissions on clinical recurrence and recurrence-free
time in ulcerative colitis. Inflamm. Bowel Dis. 23, 2238–2244 (2017).
21. Abu-Sbeih, H., Ali, F., Luo, W., Qiao, W., Raju, G. & Wang, Y. Importance of
endoscopic and histological evaluation in the management of immune check-
point inhibitor-induced colitis. J. Immunother. Cancer 6, 95 (2018).
22. Wang, Y., Abu-Sbeih, H., Mao, E., Ali, N., Qiao, W., Trinh, V. et al. Endoscopic and
histologic features of immune checkpoint inhibitor-related colitis. Inflamm. Bowel
Dis. 24, 1695–1705 (2018).
23. Ho, G., Mowat, C., Goddard, C., Fennell, J., Shah, N., Prescott, R. et al. Predicting the
outcome of severe ulcerative colitis: development of a novel risk score to aid
early selection of patients for second-line medical therapy or surgery. Aliment
Pharm. Ther. 19, 1079–1087 (2004).
24. Travis, S., Schnell, D., Krzeski, P., Abreu, M., Altman, D., Colombel, J. et al.
Developing an instrument to assess the endoscopic severity of ulcerative
colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 61,
535–542 (2012).
25. Schroeder, K., Tremaine, W. & Ilstrup, D. Coated oral 5-aminosalicylic acid therapy
for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J.
Med. 317, 1625–1629 (1987).
26. Abu-Sbeih, H., Ali, F., Wang, X., Mallepally, N., Chen, E., Altan, M. et al. Early
introduction of selective immunosuppressive therapy associated with favorable
clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J.
Immunother. Cancer 7, 93 (2019).
27. Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S. et al.
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
Cancer Immunol. Immunother. 66, 581–592 (2017).
28. Jain, A., Lipson, E., Sharfman, W., Brant, S. & Lazarev, M. Colonic ulcerations may
predict steroid-refractory course in patients with ipilimumab-mediated enter-
ocolitis. World J. Gastroenterol. 23, 2023–2028 (2017).
29. Geukes Foppen, M., Rozeman, E., van Wilpe, S., Postma, C., Snaebjornsson, P., van
Thienen, J. et al. Immune checkpoint inhibition-related colitis: symptoms, endo-
scopic features, histology and response to management. ESMO Open 3, e000278
(2018).
30. Cheung, V., Gupta, T., Olsson-Brown, A., Subramanian, S., Sasson, S., Heseltine, J.
et al. P272 Immune checkpoint inhibitor-related colitis assessment and prog-
nosis: can inflammatory bowel disease scoring point the way? J. Crohns Colitis 14,
S286–S288 (2020).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2020
Immune checkpoint inhibitor-related colitis assessment and prognosis: can. . .
VTF Cheung et al.
9
